Drug Profile
Sizavaleucel - Medeor Therapeutics
Alternative Names: MDR-101Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Medeor Therapeutics
- Class Cell therapies; Haematopoietic stem cells therapies; Immunotherapies; Stem cell therapies; T lymphocyte cell therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Renal transplant rejection
Most Recent Events
- 02 Nov 2023 Sizavaleucel - Medeor Therapeutics receives Orphan Drug status for Renal transplant rejection (Prevention) in European Union
- 02 Nov 2023 Sizavaleucel - Medeor Therapeutics receives Orphan Drug status for Renal transplant rejection (Prevention) in USA
- 02 Nov 2023 Efficacy data from phase III trial in Renal transplant rejection released by Medeor Therapeutics